Acknowledgement
This study was supported by a grant (KNRF-2019067449) from the National Research Foundation of South Korea and by the South Korean Fund for Regenerative Medicine (KFRM) grant (RS-2023-00215312) funded by the South Korean government (the Ministry of Science and ICT, the Ministry of Health & Welfare).
References
- Alewine, C., Hassan, R., and Pastan, I. (2015). Advances in anticancer immunotoxin therapy. Oncologist 20, 176-185. https://doi.org/10.1634/theoncologist.2014-0358
- Alewine, C., Xiang, L., Yamori, T., Niederfellner, G., Bosslet, K., and Pastan, I. (2014). Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol. Cancer Ther. 13, 2653-2661. https://doi.org/10.1158/1535-7163.MCT-14-0132
- Allahyari, H., Heidari, S., Ghamgosha, M., Saffarian, P., and Amani, J. (2017). Immunotoxin: a new tool for cancer therapy. Tumour Biol. 39, 1010428317692226.
- Allured, V.S., Collier, R.J., Carroll, S.F., and McKay, D.B. (1986). Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc. Natl. Acad. Sci. U. S. A. 83, 1320-1324. https://doi.org/10.1073/pnas.83.5.1320
- Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M., Lee, T., Pope, S.H., Riordan, G.S., and Whitlow, M. (1988). Single-chain antigen-binding proteins. Science 242, 423-426. https://doi.org/10.1126/science.3140379
- Cao, L., Li, Q., Tong, Z., Xing, Y., Xu, K., Wang, J.Y., Li, W., Zhao, J., Zhao, L., and Hong, Z. (2020). HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. Int. J. Pharm. 574, 118939.
- Cerise, A., Bera, T.K., Liu, X., Wei, J., and Pastan, I. (2019). Anti-mesothelin recombinant immunotoxin therapy for colorectal cancer. Clin. Colorectal Cancer 18, 192-199.e1. https://doi.org/10.1016/j.clcc.2019.06.006
- Chang, K. and Pastan, I. (1996). Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U. S. A. 93, 136-140. https://doi.org/10.1073/pnas.93.1.136
- Chang, K., Pastan, I., and Willingham, M.C. (1992). Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer 50, 373-381. https://doi.org/10.1002/ijc.2910500308
- Chaudhary, V.K., Jinno, Y., FitzGerald, D., and Pastan, I. (1990). Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 87, 308-312. https://doi.org/10.1073/pnas.87.1.308
- Dieffenbach, M. and Pastan, I. (2020). Mechanisms of resistance to immunotoxins containing pseudomonas exotoxin A in cancer therapy. Biomolecules 10, 979.
- Do, B.H., Ryu, H.B., Hoang, P., Koo, B.K., and Choe, H. (2014). Soluble prokaryotic overexpression and purification of bioactive human granulocyte colony-stimulating factor by maltose binding protein and protein disulfide isomerase. PLoS One 9, e89906.
- Ecker, M., Redpath, G.M.I., Nicovich, P.R., and Rossy, J. (2021). Quantitative visualization of endocytic trafficking through photoactivation of fluorescent proteins. Mol. Biol. Cell 32, 892-902. https://doi.org/10.1091/mbc.E20-10-0669
- Ferrer, M., Chernikova, T.N., Timmis, K.N., and Golyshin, P.N. (2004). Expression of a temperature-sensitive esterase in a novel chaperonebased Escherichia coli strain. Appl. Environ. Microbiol. 70, 4499-4504. https://doi.org/10.1128/AEM.70.8.4499-4504.2004
- Han, S.H., Joo, M., Kim, H., and Chang, S. (2017). Mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes. J Pathol. Transl. Med. 51, 122-128. https://doi.org/10.4132/jptm.2016.11.18
- Hansen, J.K., Weldon, J.E., Xiang, L., Beers, R., Onda, M., and Pastan, I. (2010). A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother. 33, 297-304. https://doi.org/10.1097/CJI.0b013e3181cd1164
- Hassan, R. and Ho, M. (2008). Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46-53. https://doi.org/10.1016/j.ejca.2007.08.028
- Ho, M., Bera, T.K., Willingham, M.C., Onda, M., Hassan, R., FitzGerald, D., and Pastan, I. (2007). Mesothelin expression in human lung cancer. Clin. Cancer Res. 13, 1571-1575. https://doi.org/10.1158/1078-0432.CCR-06-2161
- Huston, J.S., Levinson, D., Mudgett-Hunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E., and Crea, R. (1988). Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85, 5879-5883. https://doi.org/10.1073/pnas.85.16.5879
- Hyun, Y., Baek, Y., Lee, C., Ki, N., Ahn, J., Ryu, S., and Ha, N.C. (2021). Structure and function of the autolysin SagA in the type IV secretion system of Brucella abortus. Mol. Cells 44, 517-528. https://doi.org/10.14348/molcells.2021.0011
- Jiang, Q., Ghafoor, A., Mian, I., Rathkey, D., Thomas, A., Alewine, C., Sengupta, M., Ahlman, M.A., Zhang, J., Morrow, B., et al. (2020). Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci. Transl. Med. 12, eaaz7252.
- Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F.P., Gevaert, T., Simon, P., et al. (2016). Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J. Nucl. Med. 57, 27-33. https://doi.org/10.2967/jnumed.115.162024
- Khaleghi, S., Rahbarizadeh, F., Ahmadvand, D., and Hosseini, H.R.M. (2017). Anti-HER2 VHH targeted magnetoliposome for intelligent magnetic resonance imaging of breast cancer cells. Cell. Mol. Bioeng. 10, 263-272. https://doi.org/10.1007/s12195-017-0481-z
- Kim, S., Koh, S., Kang, W., and Yang, J.K. (2022). The crystal structure of L-leucine dehydrogenase from Pseudomonas aeruginosa. Mol. Cells 45, 495-501. https://doi.org/10.14348/molcells.2022.0012
- Kreitman, R.J., Hassan, R., Fitzgerald, D.J., and Pastan, I. (2009). Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer 15, 5274-5279. https://doi.org/10.1158/1078-0432.CCR-09-0062
- Kreitman, R.J. and Pastan, I. (1995). Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 307, 29-37. https://doi.org/10.1042/bj3070029
- Lee, S., Park, S., Nguyen, M.T., Lee, E., Kim, J., Baek, S., Kim, C.J., Jang, Y.J., and Choe, H. (2019). A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells. BMB Rep. 52, 496-501. https://doi.org/10.5483/BMBRep.2019.52.8.250
- Liu, W., Onda, M., Lee, B., Kreitman, R.J., Hassan, R., Xiang, L., and Pastan, I. (2012). Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. U. S. A. 109, 11782-11787. https://doi.org/10.1073/pnas.1209292109
- Nguyen, M.T., Koo, B.K., Thi Vu, T.T., Song, J.A., Chong, S.H., Jeong, B., Ryu, H.B., Moh, S.H., and Choe, H. (2014). Prokaryotic soluble overexpression and purification of bioactive human growth hormone by fusion to thioredoxin, maltose binding protein, and protein disulfide isomerase. PLoS One 9, e89038.
- Park, S., Nguyen, M.Q., Ta, H.K.K., Nguyen, M.T., Lee, G., Kim, C.J., Jang, Y.J., and Choe, H. (2021). Soluble cytoplasmic expression and purification of immunotoxin HER2(scFv)-PE24B as a maltose binding protein fusion. Int. J. Mol. Sci. 22, 6483.
- Prantner, A.M., Yin, C., Kamat, K., Sharma, K., Lowenthal, A.C., Madrid, P.B., and Scholler, N. (2018). Molecular imaging of mesothelin-expressing ovarian cancer with a human and mouse cross-reactive nanobody. Mol. Pharm. 15, 1403-1411. https://doi.org/10.1021/acs.molpharmaceut.7b00789
- Roovers, R.C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A.J., Revets, H., de Haard, H.J., and van Bergen en Henegouwen, P.M. (2007). Efficient inhibition of EGFR signaling and of tumour growth by antagonistic antiEFGR Nanobodies. Cancer Immunol. Immunother. 56, 303-317. https://doi.org/10.1007/s00262-006-0180-4
- Roovers, R.C., Vosjan, M.J., Laeremans, T., el Khoulati, R., de Bruin, R.C., Ferguson, K.M., Verkleij, A.J., van Dongen, G.A., and van Bergen en Henegouwen, P.M. (2011). A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int. J. Cancer 129, 2013-2024. https://doi.org/10.1002/ijc.26145
- Ruiz-Lopez, E. and Schuhmacher, A.J. (2021). Transportation of singledomain antibodies through the blood-brain barrier. Biomolecules 11, 1131.
- Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., and Miyajima, A. (2004). Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279, 9190-9198. https://doi.org/10.1074/jbc.M312372200
- Salema, V. and Fernandez, L.A. (2013). High yield purification of nanobodies from the periplasm of E. coli as fusions with the maltose binding protein. Protein Expr. Purif. 91, 42-48. https://doi.org/10.1016/j.pep.2013.07.001
- Sarker, A., Rathore, A.S., and Gupta, R.D. (2019). Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process. Microb. Cell Fact. 18, 5.
- Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G.E., Hellstrom, K.E., and Hellstrom, I. (1999). Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. U. S. A. 96, 11531-11536. https://doi.org/10.1073/pnas.96.20.11531
- Shahbazi-Gahrouei, D. and Abdolahi, M. (2013). Detection of MUC1- expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging. Scientific World Journal 2013, 609151.
- Shinoda, H., Shannon, M., and Nagai, T. (2018). Fluorescent proteins for investigating biological events in acidic environments. Int. J. Mol. Sci. 19, 1548.
- Shirano, Y. and Shibata, D. (1990). Low temperature cultivation of Escherichia coli carrying a rice lipoxygenase L-2 cDNA produces a soluble and active enzyme at a high level. FEBS Lett. 271, 128-130. https://doi.org/10.1016/0014-5793(90)80388-Y
- Siegall, C.B., Chaudhary, V.K., FitzGerald, D.J., and Pastan, I. (1989). Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem. 264, 14256-14261. https://doi.org/10.1016/S0021-9258(18)71671-2
- Song, J.A., Koo, B.K., Chong, S.H., Kwak, J., Ryu, H.B., Nguyen, M.T., Vu, T.T., Jeong, B., Kim, S.W., and Choe, H. (2013). Expression and purification of biologically active human FGF2 containing the b'a' domains of human PDI in Escherichia coli. Appl. Biochem. Biotechnol. 170, 67-80. https://doi.org/10.1007/s12010-013-0140-3
- Vera, A., Gonzalez-Montalban, N., Aris, A., and Villaverde, A. (2007). The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol. Bioeng. 96, 1101-1106. https://doi.org/10.1002/bit.21218
- Weldon, J.E. and Pastan, I. (2011). A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278, 4683-4700. https://doi.org/10.1111/j.1742-4658.2011.08182.x
- Weldon, J.E., Xiang, L., Zhang, J., Beers, R., Walker, D.A., Onda, M., Hassan, R., and Pastan, I. (2013). A recombinant immunotoxin against the tumorassociated antigen mesothelin reengineered for high activity, low offtarget toxicity, and reduced antigenicity. Mol. Cancer Ther. 12, 48-57. https://doi.org/10.1158/1535-7163.MCT-12-0336
- Wolf, P. and Elsasser-Beile, U. (2009). Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 299, 161-176. https://doi.org/10.1016/j.ijmm.2008.08.003
- Wood, L.A., Larocque, G., Clarke, N.I., Sarkar, S., and Royle, S.J. (2017). New tools for "hot-wiring" clathrin-mediated endocytosis with temporal and spatial precision. J. Cell Biol. 216, 4351-4365. https://doi.org/10.1083/jcb.201702188
- Wouters, Y., Jaspers, T., De Strooper, B., and Dewilde, M. (2020). Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS 17, 62.
- Xiang, Y., Sang, Z., Bitton, L., Xu, J., Liu, Y., Schneidman-Duhovny, D., and Shi, Y. (2021). Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies. Cell Syst. 12, 220-234.e9. https://doi.org/10.1016/j.cels.2021.01.003
- Yi, A.R., Lee, S.R., Jang, M.U., Park, J.M., Eom, H.J., Han, N.S., and Kim, T.J. (2009). Cloning of dextransucrase gene from Leuconostoc citreum HJP4 and its high-level expression in E. coli by low temperature induction. J. Microbiol. Biotechnol. 19, 829-835.
- Yu, L., Feng, M., Kim, H., Phung, Y., Kleiner, D.E., Gores, G.J., Qian, M., Wang, X.W., and Ho, M. (2010). Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J. Cancer 1, 141-149. https://doi.org/10.7150/jca.1.141
- Zhang, J., Khanna, S., Jiang, Q., Alewine, C., Miettinen, M., Pastan, I., and Hassan, R. (2017). Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response. Clin. Cancer Res. 23, 1564-1574. https://doi.org/10.1158/1078-0432.CCR-16-1667